Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells

Study Overview
=================
Brief Summary
-----------------
Recent studies suggest that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis. Further investigations are necessary to identify the most suitable patients to receive treatment targeting this pathway, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines.

Detailed Description
-----------------
The investigators hypothesize that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis, in particular in cases of severe sarcoidosis refractory to the various therapeutic lines. The main objective of this proposal is to evaluate the presence and stage of activation of the JAK/STAT pathway in PBMCs from inactive and active sarcoidosis patients. The second objective will be to determine the role of the JAK/STAT pathway in the formation and maintenance of granulomas and their association with the severity of sarcoidosis and fibrogenesis.

Official Title
-----------------
Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells

Conditions
-----------------
Sarcoidosis, JAK-STAT Pathway Deregulation

Intervention / Treatment
-----------------
* Other: Blood sample


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS / ERS / WASOG criteria Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other probable causal factor identified on the usual standard examination at the time of the sample with the need for diagnostic confirmation at the end of the study according to the criteria of the ATS / ERS / WASOG Sarcoidosis with stage 1 to 4 pulmonary involvement Patients who had a chest CT scan in the 6 months preceding the sample. Examination carried out as part of routine care Exclusion Criteria: Pregnancy. Opposition expressed to participation in the study. Patients on State Medical Aid.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with pulmonary sarcoidosis without signs of chest activity and recent diagnosis (<5 years)<br>Patients with pulmonary sarcoidosis without signs of chest activity (Benamore score <2) and recent diagnosis (<5 years) | Other: Blood sample<br>* Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml<br>|
| Patients with pulmonary sarcoidosis with signs of chest activity and recent diagnosis (<5 years<br>Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2) and recent diagnosis (<5 years) | Other: Blood sample<br>* Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml<br>|
| Patients with pulmonary sarcoidosis without signs of activity , persistent form (>5 years)<br>Patients with pulmonary sarcoidosis without signs of activity (Benamore score <2), persistent form (>5 years) | Other: Blood sample<br>* Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml<br>|
| Patients with pulmonary sarcoidosis with signs of chest activity , persistent form (>5 years)<br>Patients with pulmonary sarcoidosis with signs of chest activity (Benamore score ≥2), persistent form (>5 years) | Other: Blood sample<br>* Blood sample collection of 5 blood sample at the inclusion in the study the samle consite of 5 tubesEthylene Diamine Tetra Acetate (ADTA) of 7 ml<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| JAK/STAT familly numbers protein expression in PBMCs | Evaluation will be carried out by: - studying the expression of members of the JAK/STAT pathway, the expression of cytokines and chemokines phagocytosis and macrophage differentiation the expression of cytokines and chemokines | 1 year after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sarcoidosis, JAK/STAT